Navigation Links
DOR BioPharma Announces NIH Grant Award to Support Phase 1/2 Clinical Trial of DOR201 in Radiation Enteritis
Date:9/8/2009

PRINCETON, N.J., Sept. 8 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biotechnology company, announced today that the National Institutes of Health (NIH) has awarded DOR a Small Business Innovation Research (SBIR) grant to support the conduct of a Phase 1/2 clinical trial evaluating DOR201, a time-release formulation of oral beclomethasone dipropionate (oral BDP), for the prevention of acute radiation enteritis. The award will provide DOR with approximately $500,000 over a two-year period.

The grant application included the Phase 1/2 protocol BDP-ENT-01, which is designed as a multicenter, open-label, sequential, dose-escalation study in approximately 36 patients. Patients with rectal cancer who are scheduled to undergo concurrent radiation and chemotherapy prior to surgery will be enrolled in four dose groups. The objectives of the study are to evaluate the safety and maximal tolerated dose of escalating doses of DOR201, as well as the preliminary efficacy of DOR201 for prevention of signs and symptoms of acute radiation enteritis. The study is expected to be initiated in 2009.

Acute radiation enteritis is caused by radiation-induced death of cells in the lining of the bowel. As bowel cells die and are not replaced, gastrointestinal toxicity develops over the next few days and weeks due to an inflammatory response to dead cells and bacteria, with chronic diarrhea, vomiting and pain being the major symptoms. The addition of chemotherapy often exacerbates the onset, severity and debilitation related to intestinal symptoms. Radiation enteritis often results in delay or interruption of the cancer treatment. There are over 100,000 patients annually in the United States who receive abdominal or pelvic external beam radiation treatment for cancer, and these patients are at risk of developing acute and chronic radiation enteritis.

"Radi
'/>"/>

SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Research-Based Biopharmaceutical Company Awards Trials to DATATRAK
2. Eiger BioPharmaceuticals Announces Initiation of CLEAN-1 HCV Phase 1b Trial
3. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
4. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Files Three Patent Applications
5. CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders
6. DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD
7. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
8. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
9. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
10. Plasma Products Safe Despite Swine Influenza Outbreak, Assures International Biopharmaceutical Company Octapharma
11. DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... YORK , September 23, 2014 ... pioneer in computer-aided dysmorphology analysis will exhibit at the ... Diego, CA. FDNA will present the latest ... and reference solution, using facial analysis technology. Face2Gene facilitates ... of human malformations from facial photos. The ...
(Date:9/23/2014)... -- According to the new research ... Irreversible Electroporation, Cryotherapy, Microwave), Application (General & Cosmetic ... to 2019", published by MarketsandMarkets, studies the global Ablation ... to 2019. The market is expected to reach ... from 2014 to 2019. Browse 95 ...
(Date:9/23/2014)... Sept. 23, 2014  While proton therapy recently began in the ... Ashya King , another case in the United States ... young boy who was given just days to live now looks forward ... Green of Arizona complained of a headache ... medical treatments that will conclude Sept. 23, when he completes proton ...
Breaking Medicine Technology:FDNA to Exhibit at ASHG2014 Presenting Face2Gene Integrated With London Medical Databases (LMD) Online 2Ablation Technologies Market Worth $3.81 Billion by 2019 2Ablation Technologies Market Worth $3.81 Billion by 2019 3Ablation Technologies Market Worth $3.81 Billion by 2019 45-Year-Old Brain Cancer Patient Completes Proton Therapy, Awaits Kindergarten 25-Year-Old Brain Cancer Patient Completes Proton Therapy, Awaits Kindergarten 35-Year-Old Brain Cancer Patient Completes Proton Therapy, Awaits Kindergarten 4
... with Betaseron(R),(interferon beta-1b) shortly after their first clinical ... risk of developing confirmed disability,progression compared to patients ... and published in The Lancet this,week-provide the first ... on later accumulation of disability, as observed,over the ...
... PHILADELPHIA, Aug. 3 GlaxoSmithKline (NYSE:,GSK), one of ... has placed another order to purchase bulk H5N1 ... The company also announced the,start of the first ... pre-pandemic influenza program. HHS Order The ...
Cached Medicine Technology:Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression 2Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression 3Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression 4Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression 5GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSK's Candidate Pre-pandemic Flu Vaccine to Start. 2GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSK's Candidate Pre-pandemic Flu Vaccine to Start. 3GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSK's Candidate Pre-pandemic Flu Vaccine to Start. 4
(Date:9/23/2014)... If you or a loved one ... treatment may be a challenge. Fortunately, an inventor from ... is designed to improve the experience. , He developed ... having to remove, tear or reposition their clothing. Furthermore, ... their dignity. At the same time, it safeguards their ...
(Date:9/23/2014)... been shown to be a driving force behind ... develops due to chronic inflammation caused by conditions ... relatively few effective treatment options. Now, scientists at ... for the first time in preclinical studies that ... astrocyte elevated gene-1 (AEG-1) halts the development and ...
(Date:9/23/2014)... Becker's Hospital Review has published ... Hospitals and Health Systems With Great Orthopedic Programs." ... the list have orthopedic surgery departments, programs or ... reputable sources. Exceptional orthopedic departments include physicians who ... and treat professional athletes. , This is the ...
(Date:9/23/2014)... the curve of oxygen desaturation" (AUC Desat ) may ... levels during procedures using sedation, according to a study ... AUC Desat provides information not only whether blood ... duration, and rate of episodes of oxygen desaturation. ... of Cincinnati and colleagues reports on the development of ...
(Date:9/23/2014)... Contrary to what is often assumed about single parents, ... from The Kinsey Institute has found that single parents ... active as often as singles without children -- and ... The study, "Dating and Sexual Behavior Among Single Parents ... online in the Journal of Sex Research ...
Breaking Medicine News(10 mins):Health News:Apparel for Dialysis Patients Invented by InventHelp Client (CBA-2492) 2Health News:Study uncovers genetic driver of inflammation, uses it to prevent and treat liver cancer 2Health News:125 Hospitals With Great Orthopedic Programs 2Health News:125 Hospitals With Great Orthopedic Programs 3Health News:125 Hospitals With Great Orthopedic Programs 4Health News:125 Hospitals With Great Orthopedic Programs 5Health News:New measure provides more data on oxygen levels during sedation 2Health News:Kinsey study of single parents' dating, sexual activity contradicts assumptions 2
... vascular disease - a blood circulation problem that causes ... Saxton and other researchers from Sheffield Hallam University's centre ... patients aged between 50 and 85 with peripheral vascular ... cardiovascular function and walking ability of the patients improved ...
... HIV/AIDS spread – says Governor, Mr S C Jamir. ... the spread of HIV/AIDS, Governor adds. ,Many labourers ... tourist spot, bring with them the dreadful virus (HIV) when they ... Chinese proposal named ‘Four Frees and One Care’ meaning free anti-retroviral ...
... a vaccine to protect themselves from cervical cancer as the ... American pharmaceutical giant Merck. // ,The Food and ... for use in girls and women ages 9 to 26 ... of products with potential to provide significant benefits. , ...
... fertility treatment do not confide in their employers about the ... a survey carried out by the Infertility Network of ... observed that the patients were worried about not being able ... survey, done for National Infertility Day, revealed that although ...
... 1918 pandemic hit, the death toll was so overwhelming that ... to hold brief //memorial services, trains commandeered to transport dead ... Philadelphia. ,With the threat of another flu pandemic ... and health care providers making preparations for it mortuary specialists ...
... A new study in UK reports, parents believe more than ... one year old children are found //to avoid certain foods ... compulsion - Dr. Taraneh Dean of the University of Portsmouth ... Journal of Allergy and Clinical Immunology as only 2 – ...
Cached Medicine News:Health News:What to do with the Dead if a Flu Outbreak Happens? 2
... for the Humphrey Field Analyzer, SITA ... shows less inter-test variability than Full ... of reproducibility as Full Threshold SWAP. ... with the earlier glaucoma damage detected ...
... you can trust its capabilities will ... cataract, and glaucoma therapy in one ... is the optimal system for photocoagulation, ... iridotomy. The push of a button ...
... The VISUCAM non-mydriatic ... quality and simplicity of ... big enough to set ... photography, it features a ...
... YAG III is the new disruption ... in particular for applications in posterior ... the YAG laser is also used ... IOL polishing. It's another milestone in ...
Medicine Products: